145 related articles for article (PubMed ID: 29940898)
1. Dual effects of the Nrf2 inhibitor for inhibition of hepatitis C virus and hepatic cancer cells.
Murakami Y; Sugiyama K; Ebinuma H; Nakamoto N; Ojiro K; Chu PS; Taniki N; Saito Y; Teratani T; Koda Y; Suzuki T; Saito K; Fukasawa M; Ikeda M; Kato N; Kanai T; Saito H
BMC Cancer; 2018 Jun; 18(1):680. PubMed ID: 29940898
[TBL] [Abstract][Full Text] [Related]
2. Brusatol provokes a rapid and transient inhibition of Nrf2 signaling and sensitizes mammalian cells to chemical toxicity-implications for therapeutic targeting of Nrf2.
Olayanju A; Copple IM; Bryan HK; Edge GT; Sison RL; Wong MW; Lai ZQ; Lin ZX; Dunn K; Sanderson CM; Alghanem AF; Cross MJ; Ellis EC; Ingelman-Sundberg M; Malik HZ; Kitteringham NR; Goldring CE; Park BK
Free Radic Biol Med; 2015 Jan; 78():202-12. PubMed ID: 25445704
[TBL] [Abstract][Full Text] [Related]
3. Inhibition of Nrf2-mediated glucose metabolism by brusatol synergistically sensitizes acute myeloid leukemia to Ara-C.
Cheng C; Yuan F; Chen XP; Zhang W; Zhao XL; Jiang ZP; Zhou HH; Zhou G; Cao S
Biomed Pharmacother; 2021 Oct; 142():111652. PubMed ID: 34112534
[TBL] [Abstract][Full Text] [Related]
4. Brusatol Enhances the Radiosensitivity of A549 Cells by Promoting ROS Production and Enhancing DNA Damage.
Sun X; Wang Q; Wang Y; Du L; Xu C; Liu Q
Int J Mol Sci; 2016 Jun; 17(7):. PubMed ID: 27347930
[TBL] [Abstract][Full Text] [Related]
5. Nrf2 Inhibitor, Brusatol in Combination with Trastuzumab Exerts Synergistic Antitumor Activity in HER2-Positive Cancers by Inhibiting Nrf2/HO-1 and HER2-AKT/ERK1/2 Pathways.
Yang Y; Tian Z; Guo R; Ren F
Oxid Med Cell Longev; 2020; 2020():9867595. PubMed ID: 32765809
[TBL] [Abstract][Full Text] [Related]
6. Brusatol enhances the efficacy of chemotherapy by inhibiting the Nrf2-mediated defense mechanism.
Ren D; Villeneuve NF; Jiang T; Wu T; Lau A; Toppin HA; Zhang DD
Proc Natl Acad Sci U S A; 2011 Jan; 108(4):1433-8. PubMed ID: 21205897
[TBL] [Abstract][Full Text] [Related]
7. Comprehensive anti-tumor effect of Brusatol through inhibition of cell viability and promotion of apoptosis caused by autophagy via the PI3K/Akt/mTOR pathway in hepatocellular carcinoma.
Ye R; Dai N; He Q; Guo P; Xiang Y; Zhang Q; Hong Z; Zhang Q
Biomed Pharmacother; 2018 Sep; 105():962-973. PubMed ID: 30021391
[TBL] [Abstract][Full Text] [Related]
8. Anti-ulcer agent teprenone inhibits hepatitis C virus replication: potential treatment for hepatitis C.
Ikeda M; Kawai Y; Mori K; Yano M; Abe K; Nishimura G; Dansako H; Ariumi Y; Wakita T; Yamamoto K; Kato N
Liver Int; 2011 Jul; 31(6):871-80. PubMed ID: 21645219
[TBL] [Abstract][Full Text] [Related]
9. Inhibitory effects of Pycnogenol® on hepatitis C virus replication.
Ezzikouri S; Nishimura T; Kohara M; Benjelloun S; Kino Y; Inoue K; Matsumori A; Tsukiyama-Kohara K
Antiviral Res; 2015 Jan; 113():93-102. PubMed ID: 25446333
[TBL] [Abstract][Full Text] [Related]
10. Application of Mass Spectrometry Profiling to Establish Brusatol as an Inhibitor of Global Protein Synthesis.
Vartanian S; Ma TP; Lee J; Haverty PM; Kirkpatrick DS; Yu K; Stokoe D
Mol Cell Proteomics; 2016 Apr; 15(4):1220-31. PubMed ID: 26711467
[TBL] [Abstract][Full Text] [Related]
11. Brusatol-Mediated Inhibition of c-Myc Increases HIF-1α Degradation and Causes Cell Death in Colorectal Cancer under Hypoxia.
Oh ET; Kim CW; Kim HG; Lee JS; Park HJ
Theranostics; 2017; 7(14):3415-3431. PubMed ID: 28912885
[TBL] [Abstract][Full Text] [Related]
12. Nrf2 inhibition affects cell cycle progression during early mouse embryo development.
Lin Y; Sui LC; Wu RH; Ma RJ; Fu HY; Xu JJ; Qiu XH; Chen L
J Reprod Dev; 2018 Feb; 64(1):49-55. PubMed ID: 29249781
[TBL] [Abstract][Full Text] [Related]
13. Liver-specific mono-unsaturated fatty acid synthase-1 inhibitor for anti-hepatitis C treatment.
Nio Y; Hasegawa H; Okamura H; Miyayama Y; Akahori Y; Hijikata M
Antiviral Res; 2016 Aug; 132():262-7. PubMed ID: 27392483
[TBL] [Abstract][Full Text] [Related]
14. Brusatol: A potential sensitizing agent for cancer therapy from Brucea javanica.
He T; Zhou F; Su A; Zhang Y; Xing Z; Mi L; Li Z; Wu W
Biomed Pharmacother; 2023 Feb; 158():114134. PubMed ID: 36525821
[TBL] [Abstract][Full Text] [Related]
15. Brusatol overcomes chemoresistance through inhibition of protein translation.
Harder B; Tian W; La Clair JJ; Tan AC; Ooi A; Chapman E; Zhang DD
Mol Carcinog; 2017 May; 56(5):1493-1500. PubMed ID: 28019675
[TBL] [Abstract][Full Text] [Related]
16. The kinase-inhibitor sorafenib inhibits multiple steps of the Hepatitis C Virus infectious cycle in vitro.
Descamps V; Helle F; Louandre C; Martin E; Brochot E; Izquierdo L; Fournier C; Hoffmann TW; Castelain S; Duverlie G; Galmiche A; François C
Antiviral Res; 2015 Jun; 118():93-102. PubMed ID: 25823619
[TBL] [Abstract][Full Text] [Related]
17. Brusatol inhibits growth and induces apoptosis in pancreatic cancer cells via JNK/p38 MAPK/NF-κb/Stat3/Bcl-2 signaling pathway.
Xiang Y; Ye W; Huang C; Lou B; Zhang J; Yu D; Huang X; Chen B; Zhou M
Biochem Biophys Res Commun; 2017 Jun; 487(4):820-826. PubMed ID: 28455228
[TBL] [Abstract][Full Text] [Related]
18. A cell-based, high-throughput screen for small molecule regulators of hepatitis C virus replication.
Kim SS; Peng LF; Lin W; Choe WH; Sakamoto N; Kato N; Ikeda M; Schreiber SL; Chung RT
Gastroenterology; 2007 Jan; 132(1):311-20. PubMed ID: 17241881
[TBL] [Abstract][Full Text] [Related]
19. Anti-hepatitis C virus activity and synergistic effect of Nymphaea alba extracts and bioactive constituents in liver infected cells.
Rehman S; Ashfaq UA; Ijaz B; Riazuddin S
Microb Pathog; 2018 Aug; 121():198-209. PubMed ID: 29775725
[TBL] [Abstract][Full Text] [Related]
20. The toxic effects and possible mechanisms of Brusatol on mouse oocytes.
Ma R; Li H; Zhang Y; Lin Y; Qiu X; Xie M; Yao B
PLoS One; 2017; 12(5):e0177844. PubMed ID: 28542354
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
